StreetInsider.com News Articles

Form S-3ASR BridgeBio Pharma, Inc.

Fri, 24 Jul 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260724/26814367.html

Form S-3ASR BridgeBio Pharma, Inc.

Fri, 24 Jul 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260724/26814367.html

Form S-8 BridgeBio Pharma, Inc.

Fri, 24 Jul 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260724/26814347.html

Form S-8 BridgeBio Pharma, Inc.

Fri, 24 Jul 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260724/26814347.html

H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Fri, 24 Jul 2026 07:26:01 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $120.00 price target on BridgeBio Pharma (NASDAQ: BBIO).

The analyst commented: "Encaleret application accepted for review, with potential regulatory approval in May 2027. This week, BridgeBio announced the that FDA has accepted for filing its New Drug Application (NDA) for encaleret for the treatment of individuals living with autosomal dominant hypocalcemia type 1 (ADH1). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 8, 2027, and BridgeBio is prepared to launch encaleret in the U.S. upon approval, targeting a potential blockbuster opportunity. The FDA

Form 8-K BridgeBio Pharma, Inc. For: Jul 22

Wed, 22 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260722/26802192.html

Form 8-K BridgeBio Pharma, Inc. For: Jul 22

Wed, 22 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260722/26802192.html

FDA accepts BridgeBio NDA for encaleret to treat ADH1

Wed, 22 Jul 2026 07:31:29 -0400

BridgeBio Pharma (Nasdaq: BBIO) announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for encaleret, an investigational oral treatment for autosomal dominant hypocalcemia type 1 (ADH1), a genetic form of hypoparathyroidism.

The FDA assigned a PDUFA target action date of May 8, 2027. The agency also notified BridgeBio that it does not currently plan to hold an advisory committee meeting to discuss the application.

Encaleret is a small molecule designed to selectively modulate the calcium-sensing receptor. The drug has received Fast Track Designation and Orphan Drug Designation in the U.S., European Union, and Japan. If

FDA accepts BridgeBio NDA for encaleret to treat ADH1

Wed, 22 Jul 2026 07:31:29 -0400

The FDA assigned a PDUFA target action date of May 8, 2027. The agency also notified BridgeBio that it does not currently plan to hold an advisory committee meeting to discuss the application.

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

Wed, 22 Jul 2026 07:30:00 -0400

- PDUFA target action date of May 8, 2027

- If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbuster opportunity for BridgeBio

- Encaleret demonstrated consistent efficacy across all pre-specified primary and key secondary efficacy endpoints normalizing key markers of CaSR-driven disease biology without the need for calcium and vitamin D supplements, with a favorable safety and tolerability profile

- BridgeBio is also currently enrolling CALIBRATE-PEDS, a registrational Phase 2/3 trial to study encaleret in pediatric ADH1 and intends to initiate the RECLAIM-HP Phase

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

Wed, 22 Jul 2026 07:30:00 -0400

- PDUFA target action date of May 8, 2027

- If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbuster opportunity for BridgeBio

- Encaleret demonstrated consistent efficacy across all pre-specified primary and key secondary efficacy endpoints normalizing key markers of CaSR-driven disease biology without the need for calcium and vitamin D supplements, with a favorable safety and tolerability profile

- BridgeBio is also currently enrolling CALIBRATE-PEDS, a registrational Phase 2/3 trial to study encaleret in pediatric ADH1 and intends to initiate the RECLAIM-HP Phase

BridgeBio Pharma (BBIO) PT Raised to $93 at Citi

Thu, 16 Jul 2026 05:03:48 -0400
Citi analyst Eric Joseph raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $93.00 (from $82.00) while maintaining a Neutral rating.

Form 4 BridgeBio Pharma, Inc. For: Jul 09 Filed by: Ellis Andrea

Mon, 13 Jul 2026 16:42:00 -0400
si-local-file:///var/storage/secattach/20260713/26762973.html

Form 4 BridgeBio Pharma, Inc. For: Jul 09 Filed by: Ellis Andrea

Mon, 13 Jul 2026 16:42:00 -0400
si-local-file:///var/storage/secattach/20260713/26762973.html

Form 4 BridgeBio Pharma, Inc. For: Jul 09 Filed by: Cook Jennifer E.

Mon, 13 Jul 2026 16:40:00 -0400
si-local-file:///var/storage/secattach/20260713/26762958.html

Form 4 BridgeBio Pharma, Inc. For: Jul 09 Filed by: Cook Jennifer E.

Mon, 13 Jul 2026 16:40:00 -0400
si-local-file:///var/storage/secattach/20260713/26762958.html

BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright

Mon, 13 Jul 2026 06:41:49 -0400
(Updated - July 13, 2026 6:41 AM EDT)
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $120.00 (from $110.00) while maintaining a Buy rating.
The analyst commented: "Late last week, Ionis Pharmaceuticals and its partner AstraZeneca plc reported that the CARDIO-TTRansform Phase 3 trial of their agent Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to 140 weeks vs. placebo. In this contemporary patient population treated with standard-of-care interventions, including a majority on

BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright

Mon, 13 Jul 2026 06:41:49 -0400
(Updated - July 13, 2026 6:41 AM EDT)
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $120.00 (from $110.00) while maintaining a Buy rating.
The analyst commented: "Late last week, Ionis Pharmaceuticals and its partner AstraZeneca plc reported that the CARDIO-TTRansform Phase 3 trial of their agent Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to 140 weeks vs. placebo. In this contemporary patient population treated with standard-of-care interventions, including a majority on

BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright

Mon, 13 Jul 2026 06:41:49 -0400
(Updated - July 13, 2026 6:41 AM EDT)
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $120.00 (from $110.00) while maintaining a Buy rating.
The analyst commented: "Late last week, Ionis Pharmaceuticals and its partner AstraZeneca plc reported that the CARDIO-TTRansform Phase 3 trial of their agent Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to 140 weeks vs. placebo. In this contemporary patient population treated with standard-of-care interventions, including a majority on

BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright

Mon, 13 Jul 2026 06:41:49 -0400
(Updated - July 13, 2026 6:41 AM EDT)
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $120.00 (from $110.00) while maintaining a Buy rating.
The analyst commented: "Late last week, Ionis Pharmaceuticals and its partner AstraZeneca plc reported that the CARDIO-TTRansform Phase 3 trial of their agent Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to 140 weeks vs. placebo. In this contemporary patient population treated with standard-of-care interventions, including a majority on

BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright

Mon, 13 Jul 2026 06:41:49 -0400
(Updated - July 13, 2026 6:41 AM EDT)
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $120.00 (from $110.00) while maintaining a Buy rating.
The analyst commented: "Late last week, Ionis Pharmaceuticals and its partner AstraZeneca plc reported that the CARDIO-TTRansform Phase 3 trial of their agent Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to 140 weeks vs. placebo. In this contemporary patient population treated with standard-of-care interventions, including a majority on

BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright

Mon, 13 Jul 2026 06:41:49 -0400
(Updated - July 13, 2026 6:41 AM EDT)
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $120.00 (from $110.00) while maintaining a Buy rating.
The analyst commented: "Late last week, Ionis Pharmaceuticals and its partner AstraZeneca plc reported that the CARDIO-TTRansform Phase 3 trial of their agent Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to 140 weeks vs. placebo. In this contemporary patient population treated with standard-of-care interventions, including a majority on

Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP

Fri, 10 Jul 2026 19:03:00 -0400
si-local-file:///var/storage/secattach/20260710/26758251.html

Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP

Fri, 10 Jul 2026 19:03:00 -0400
si-local-file:///var/storage/secattach/20260710/26758251.html

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:01:00 -0400

PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on July 7, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 37 new employees in restricted stock units for an aggregate of 83,283 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly